HOME >> MEDICINE >> NEWS
First large-scale clinical study establishes the efficacy of the new oral anticoagulant H 376/95

at high risk of venous thrombosis (formation of a blood clot in a vein) which may result in pulmonary embolism leading to death. A common approach to prevention of venous thromboembolism is the use of anticoagulant prophylaxis e.g. injectable low molecular weight heparin or oral warfarin. Warfarin requires careful and regular coagulation monitoring i.e. taking blood samples. Warfarin has limitations because of a slow onset of effect over several days. Also, bleeding complications and drug interactions are common. There is, therefore, a need for an effective and well-tolerated oral alternative to warfarin. The data from the METHRO II study indicate that H 376/95 shows considerable promise as a replacement for low molecular weight heparin and warfarin in the prophylaxis of venous thromboembolism in orthopaedic surgery."

The METHRO II study was a double-blind, dose-finding study and a comparator agent was used. The primary purpose of the study was to determine the dose-response relationship with regard to efficacy for the oral direct thrombin inhibitor, H 376/95, preceded by subcutaneous administration of melagatran. The METHRO II study was also designed to compare the efficacy of the H 376/95 regimen with conventional prophylaxis using the injectable low molecular weight heparin agent, dalteparin.

Patients were randomised to one of four melagatran/H 376/95 regimens or dalteparin for 8-11 days. The regimens were: 1mg, 1.5mg, 2.25mg or 3mg melagatran subcutaneously twice daily followed by 8mg, 12mg, 18mg or 24mg oral H 376/95 twice daily respectively or dalteparin 5000 IU once daily subcutaneously. A diagnostic procedure, phlebography, was carried out on the final day of treatment. Patient follow-up was 4-6 weeks post-operatively. Two-thirds of the patients underwent hip replacement and one-third knee replacement surgery. The age range was 18-85 years.

There was a clear relationship between the dose regimen of H 376/95 and the occurrence of
'"/>

Contact: Jonathan Wilson/Rebecca Hunt
jonathan.wilson@ketchumcomms.co.uk
44-207-465-7698
Ketchum
4-May-2000


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a ... and business owners in the greater Dallas metropolitan area, is announcing a charity ... Foundation. , Established in 2009 by active police professionals in the Dallas region, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally ... Your Health on Voice of America, declared on her radio program in November 2016 ... fact that when these bullies attack leaders in corporate America, they are trying to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., ... Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience ... to help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( ... cavernous angiomas, was awarded a grant from the Julian Grace Foundation to increase ... has more people with cavernous angioma than anywhere in the world. Most share ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC ... a recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 ... the same target on B cells as Rituxan and ... components but is also involved in tumor targeting, engagement ... vaccine effect. The results of the study (abstract #95954) ...
(Date:12/6/2016)... 2016 Homozygous Familial Hypercholesterolemia (HoFH) ... Global Markets Direct,s latest Pharmaceutical and ... (HoFH) – Pipeline Review, H2 2016, provides ... (HoFH) (Metabolic Disorders) pipeline landscape. Homozygous ... is caused due to mutation from both ...
(Date:12/6/2016)... CENTENNIAL, Colo. , Dec. 6, 2016 /PRNewswire-USNewswire/ ... providers of cartilage, cellular, bone, skin and soft-tissue ... Kimberly Meyer , Business Process Manager, for being ... 2016 Malcolm Baldrige National Quality Award by the ... (NIST), deepening the organization,s commitment to process excellence. ...
Breaking Medicine Technology:
Cached News: